Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494930 | 0.94 | ACACB (0.72) | ACACBACACA | |
| SCHEMBL3494778 | 0.91 | ACACB (0.82) | ACACBACACA | |
| SCHEMBL13402320 | 0.90 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL3496784 | 0.90 | ACACB (0.85) | ACACBACACA | |
| SCHEMBL3494374 | 0.87 | ACACB (0.66) | ACACBACACA | |
| SCHEMBL3496566 | 0.84 | ACACB (0.75) | ACACBACACA | |
| SCHEMBL3498959 | 0.83 | ACACB (0.86) | ACACBACACA | |
| SCHEMBL4724597 | 0.83 | ACACB (0.89) | ACACBACACA | |
| SCHEMBL3497361 | 0.82 | ACACB (0.85) | ACACBACACA | |
| SCHEMBL3496642 | 0.82 | ACACB (0.80) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | ACACB 3/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.